Clene Inc. Announces Biomarker Analyses for NDA; Updates Corporate Presentation

What Happened
On August 10, 2026, Clene Inc. (CLNN) filed a Current Report on Form 8‑K disclosing two items: an updated corporate presentation posted on its investor site (invest.clene.com) and a press release announcing that biomarker analyses will be included in the company’s NDA submission supporting accelerated approval for ALS. The corporate presentation is furnished as Exhibit 99.1 and the press release as Exhibit 99.2 to the 8‑K.

Key Details

• Filing date: August 10, 2026 (Form 8‑K Items 7.01 Regulation FD disclosure and 8.01 Other Events).
• Updated corporate presentation made available on invest.clene.com (Exhibit 99.1).
• Press release states biomarker analyses will be included in Clene’s NDA submission to support ALS accelerated approval (Exhibit 99.2).
• Materials are furnished with the 8‑K (see Exhibits 99.1 and 99.2).

Why It Matters
Including biomarker analyses in an NDA submission is a regulatory and scientific detail investors watch because it can affect the FDA’s review of a drug application and the company’s case for accelerated approval. The updated presentation and press release give investors direct access to Clene’s public messaging about its regulatory strategy for ALS; shareholders should review the exhibits for specifics and monitor subsequent regulatory filings and company updates for timelines and additional data.